DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



Cardiology Homepage

Bone density scans can predict risk of cardiovascular disease New study highlights a novel way to assess the degree of vascular calcification

PET beats SPECT for detecting coronary artery disease: study Detected 79 percent of severe obstructive cases versus 70 percent

Siemens launches ACUSON Bonsai portable cardiovascular ultrasound at ACC Premium features in a smaller footprint

Canon acquires cardiac IT manufacturer Fysicon Obtains wide portfolio of monitoring systems sold globally

World's smallest mechanical heart valve scores FDA approval Meets the needs of young pediatric patients

VoCare develops Vitals360 Can assess six vitals in chronic disease management

ACC outlines how to prevent cardiac device hacking in new paper Mitigating risk to pacemakers and ICDs

FDA greenlights AI software for stroke warning in CT analysis Enables specialists to intervene before notified by a radiologist

Gadolinium could light way to stroke assessment through the eyes Could eye evaluations replace brain imaging for stroke assessment?

European Heart Rhythm Association recommends remote navigation tech to reduce occupational radiation exposure Replacement for heavy lead aprons

Spectranetics' Stellarex
drug-coated balloon

Philips to acquire cardiac device company Spectranetics for €1.9 billion

by Lauren Dubinsky , Senior Reporter
Royal Philips announced a €1.9 billion deal on Wednesday to acquire The Spectranetics Corporation, with the goal of expanding its Image-Guided Therapy Business Group.

“Today’s exciting announcement follows a series of bolt-on acquisitions to strengthen our portfolio across the health continuum,” Frans van Houten, CEO of Philips, said in the announcement.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

Late last week, Philips made an agreement to acquire the EEG technology manufacturer, Electrical Geodesics Inc., for approximately €32.9 million. In 2014, the company purchased the catheter-based imaging company, Volcano Corporation, for $1.2 billion.

Spectranetics is a leader in the fields of vascular intervention and lead management, which involves the minimally-invasive removal of implanted pacemakers and ICD leads. The company is currently growing in the double digits and expects its 2017 sales to be in the range of $293 million to $306 million.

Its portfolio includes a line of laser atherectomy catheters for treating blockages in coronary and peripheral arteries and the AngioSculpt scoring balloon to mechanically push the blockage aside. It also sells the only drug-coated scoring balloon on the market, which is called AngioSculptX, as well as the Stellarex drug-coated balloon that treats common to complex lesions and prevents blockage recurrence.

The Stellarex, which is CE marked and is under review for FDA approval, is Spectranetics’ most popular product. It’s been studied in drug-coated balloon IDE trials on the most complex patient population and demonstrated excellent clinical performance.

Philips is already a major player in the image-guided therapy market, which is valued at more than €6 billion. The company believes that Spectranetics will help it further expand and strengthen its stake in the market.

“Spectranetics’ highly competitive product range, integrated with our portfolio of interventional imaging systems, devices, software and services will enable clinicians to decide, guide, treat and confirm the appropriate cardiac and peripheral vascular treatment,” said van Houten.

“We believe that [Spectranetics’] product portfolio complements the Volcano vascular imaging [including intravascular ultrasound or IVUS and fractional flow reserve or FFR] and therapeutic product portfolio,” Mike Matson, analyst at Needham, told Yahoo! Finance.

He added that given the premium Philips is paying, and the short list of other potential buyers, that another bidder is unlikely.

Once the transaction is complete, Spectranetics and its 900-plus employees will become part of Philips’ Image-Guided Therapy Business Group, also known as Philips Volcano. The group is expected to grow to about €1 billion by 2020.

Philips plans to have the deal close in the third quarter of this year.

Cardiology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.